Gulzhan Abuova

Prof. Gulzhan Abuova

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
NPNatalia Pshenichnaya
Natalia Pshenichnaya
HLHakan Leblebicioglu
Hakan Leblebicioglu
IBIlkay Bozkurt
Ilkay Bozkurt
ISIrina Viktorovna Sannikova
Irina Viktorovna Sannikova
Gulzhan AbuovaGulzhan Abuova
Gulzhan Abuova
TFTom E. Fletcher
Tom E. Fletcher
Crimean-Congo hemorrhagic fever (CCHF) is acute viral infection and a major emerging infectious diseases threat, affecting a large geographical area. There is no proven antiviral therapy and it has a case fatality rate of 4-30%. The natural history of disease and outcomes of CCHF in pregnant women is poorly understood. To systematically review the characteristics of CCHF in pregnancy, and report a case series of 8 CCHF cases in pregnant women from Russia, Kazakhstan and Turkey. A systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement protocol. PubMed, SCOPUS, Science Citation Index (SCI) were searched for reports published between January 1960 and June 2016. Two independent reviewers selected and reviewed studies and extracted data. Thirty-four cases of CCHF in pregnancy were identified, and combined with the case series data, 42 cases were analyzed. The majority of cases originated in Turkey (14), Iran (10) and Russia (6). There was a maternal mortality of 14/41(34%) and fetal/neonatal mortality of in 24/41 cases (58.5%). Hemorrhage was associated with maternal (p=0.009) and fetal/neonatal death (p<0.0001). There was nosocomial transmission to 38 cases from 6/37 index pregnant cases. Cases of CCHF in pregnancy are rare, but associated with high rates of maternal and fetal mortality, and nosocomial transmission.

1 September 2018 in Emerging Infectious Diseases
Verified
Journal Article
Open access
Onder ErgonulOnder Ergonul
Onder Ergonul
ŞKŞiran Keske
Şiran Keske
MÇMelis Gökçe Çeldir
Melis Gökçe Çeldir
IKİlAyda Arjen Kara
İlAyda Arjen Kara
NPNatalia Pshenichnaya
Natalia Pshenichnaya
MGMehmet Gönen
Mehmet Gönen
We performed a systematic review and meta-analysis on the effectiveness of ribavirin use for the prevention of infection and death of healthcare workers exposed to patients with Crimean-Congo hemorrhagic fever virus (CCHFV) infection. Splashes with blood or bodily fluids (odds ratio [OR] 4.2), being a nurse or physician (OR 2.1), and treating patients who died from CCHFV infection (OR 3.8) were associated with healthcare workers acquiring CCHFV infection; 7% of the workers who received postexposure prophylaxis (PEP) with ribavirin and 89% of those who did not became infected. PEP with ribavirin reduced the odds of infection (OR 0.01, 95% CI 0-0.03), and ribavirin use <48 hours after symptom onset reduced the odds of death (OR 0.03, 95% CI 0-0.58). The odds of death increased 2.4-fold every day without ribavirin treatment. Ribavirin should be recommended as PEP and early treatment for workers at medium-to-high risk for CCHFV infection.

1 February 2018 in Antiviral Research
Verified
Journal Article
Closed access
HLHakan Leblebicioglu
Hakan Leblebicioglu
JAJoop E. Arends
Joop E. Arends
ROResat Ozaras
Resat Ozaras
GCGiampaolo Corti
Giampaolo Corti
LSLurdes Santos
Lurdes Santos
DSDominique Salmon
Dominique Salmon

28 February 2024 in Наука и здравоохранение
Verified
Journal Article
Open access
Gulzhan AbuovaGulzhan Abuova
Gulzhan Abuova
KKKhangeldy K.ZH.
Khangeldy K.ZH.
GSGulbanu Shaimerdenova
Gulbanu Shaimerdenova
ZBZhorakhanova B.A.
Zhorakhanova B.A.
SDSadykhova D.K.
Sadykhova D.K.
Relevance. From 600 thousand to 1.2 million cases of ARVI and influenza are registered annually in Kazakhstan. On the average for the epidemiological season hospitalised with severe and medium - severe course of ARVI - up to 70-80 thousand people, 70% of whom are children under 14 years, including children under 1 year - up to 30-35%, pregnant women -53-55% of the number of pregnant women who fall ill with ARVI, respectively. Treatment of acute respiratory viral infectious disease (ARVI) includes a number of measures and approaches aimed at alleviating symptoms, reducing the duration of the disease and preventing complications. One such drug is enisamia iodide, produced by Pharmak (Ukraine) under the trade name Amizon, registered in the Republic of Kazakhstan as an antiviral agent. Materials and methods. The study is a cohort, clinical, non-interventional, prospective. In the city infectious diseases hospital of Shymkent, clinical trials were conducted on the effectiveness of the antiviral drug enisamia iodide in severe forms of ARVI in adults, in comparison with a group of patients who did not receive etiotropic treatment from December 2022 to January 2023. Results and conclusions. As a result of the treatment, progression of normalization of body temperature was observed by the 4th and 5th days (96% and 98%, respectively). In the comparison group, an improvement in the normalization of body temperature by the 3rd day was registered in 60% of patients. When comparing the main and control groups by bed days, statistically significant differences were established (p=0.049*). Patients with standard therapy stayed in the hospital longer than those who received Amizon additionally. During treatment with Amizon, only 1 case out of 50 developed an adverse event in the form of a minor headache coinciding with the drug intake, which did not require discontinuation of the drug. On the 3rd and 4th days of therapy, statistically significant differences were revealed. Regression of intoxication symptoms (fever, chills, headache, body aches) and catarrhal manifestations occurred much earlier than in the control group. The need to prescribe antibacterial drugs during the use of Amizon was 10%, which indicates its antiviral and antibacterial effect. Актуальность. В Республике Казахстан (РК) ежегодно регистрируется от 600 тысяч до 1,2 млн. случаев ОРВИ и гриппа. В среднем за эпидемиологический сезон госпитализируется с тяжелым и средне - тяжелым течением ОРВИ – до 70-80 тысяч человек, 70% из которых составляют дети до 14 лет, в том числе дети до 1 года – до 30-35%, беременные – 53-55% от числа заболевших ОРВИ беременных соответственно. Лечение острого респираторного вирусного инфекционного заболевания (ОРВИ) включает ряд мер и подходов, направленных на облегчение симптомов, снижение длительности болезни и предотвращение осложнений. Одним из таких препаратов является энисамия иодид, производимый заводом Фармак (Украина) под торговым названием «Амизон», зарегистрированный в РК в качестве противовирусного средства. Материалы и методы. Исследование является когортным, клиническим, неинтерванционным, проспективным. В городской инфекционной больнице г. Шымкента проведены клинические испытания эффективности противовирусного препарата энисамия йодид при тяжелых формах ОРВИ у взрослых, в сравнении с группой пациентов, не получавших этиотропное лечение с декабря 2022 года по январь 2023г. Результаты и выводы. В результате проведенного лечения наблюдалась нормализация температуры тела к 4-му и 5-му дню у 96% и 98% больных соответственно. В группе сравнения нормализация температуры тела к 3-му дню зарегистрирована у 60% больных. При сравнении основной и контрольной групп по койко-дням были установлены статистически значимые различия (p=0,049*). Пациенты со стандартной терапией находились в стационаре дольше, чем те, которые получали Амизон дополнительно. На фоне лечения Амизоном только в 1 случае из 50 развилось нежелательное явление в виде незначительной головной боли, совпадающей по времени с приемом препарата, не потребовавшее отмены препарата. На 3 и 4-й день терапии выявлены статистические значимые различия. Регресс симптомов интоксикации (лихорадка, озноб, головная боль, ломота в теле) и катаральных проявлений происходил значительно раньше, чем в группе контроля....

OIOmega Mathew Immanuel
Omega Mathew Immanuel
OFOlaoluwa Tolulope Fabiyi
Olaoluwa Tolulope Fabiyi
Kuat OshakbayevKuat Oshakbayev
Kuat Oshakbayev
Gulzhan AbuovaGulzhan Abuova
Gulzhan Abuova
AKAliya Konysbekova
Aliya Konysbekova
SASyed Hani Abidi
Syed Hani Abidi
Background: In recent decades, research on Hepatitis C Virus (HCV) drug-resistant variants has expanded; however, critical gaps remain in our understanding of global contributions, emerging trends, and future research directions. Here, we present a bibliometric analysis to understand the research themes and trends in research related to HCV drug-resistant variants published between 1999 and 2025. Methods: Publications related to HCV drug-resistant variants published between 1999 and 2025 were searched on the Web of Science and Scopus databases. Publication metadata and content-based data were extracted and analyzed using Bibliometrix and VOSviewer for keyword co-occurrence plot and cluster analysis. Results: The analysis of 653 articles revealed a clear paradigm shift, driven by the introduction of direct-acting antivirals (DAAs), which led to a significant surge in annual publications, peaking between 2014 and 2018. This shift in focus led to an emphasis on DAA efficacy, resistance mechanisms, and advanced genotyping. The United States was the most productive country, with the highest number of publications (n = 134) and citations (n = 6458). The University of São Paulo was the most productive institution (n = 40), while Antimicrobial Agents and Chemotherapy published the highest number of articles in this field (n = 40). Susser S. was the most productive researcher. Collaboration networks were found to be predominantly centered in high-income countries. Analysis of studies on minority variants showed that most studies originated from Europe and the United States, identifying low-frequency resistance-associated substitutions (RASs) such as A156V, D168V, Y93H, and S282T, with prevalence ranging from <1% to 35%, which were frequently associated with viral breakthrough and reduced treatment response. Conclusions: The field successfully transitioned to the DAA era, but research output and collaboration networks were primarily driven by high-income countries, leaving a critical gap in data from Low- and Middle-Income Countries (LMICs). Closing this gap by integrating LMIC data is the next essential step to ensure global elimination strategies are effective for all countries from different income strata.

11 December 2022 in Archives of Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
Gulzhan AbuovaGulzhan Abuova
Gulzhan Abuova
NPNatalia Pshenichnaya
Natalia Pshenichnaya
LKLudmila Stanislavovna Karan'
Ludmila Stanislavovna Karan'
FBFarida Abdullaevna Berdaliyeva
Farida Abdullaevna Berdaliyeva
DADaulet Sabyrovich Aliyev
Daulet Sabyrovich Aliyev
SNSymbat Doszhanovna Nurmagambet
Symbat Doszhanovna Nurmagambet
Background: The Turkestan region of Kazakhstan is the natural focus of the Congo-Crimean hemorrhagic fever (CCHF). Every year, some of the patients treated in hospitals are not included in official statistics and remain in the group of possible cases of CCHF. Objectives: This study aimed to verify the genotypes of the CCHF virus (CCHFV) in the Turkestan region and Shymkent City. Methods: Twelve blood samples from patients with CCHF were studied, the diagnosis of which was verified on the basis of positive specific immunoglobulins IgM to the virus. To isolate viral RNA, we used a special MAGNO-sorb kit. To detect RNA, CCHFV was used with a set of Amplisens CCHFV-FL by real-time polymerase chain reaction (PCR) using a Rotor-Gene Q device. For the reverse transcription reaction, we used a set of Reverta-L. Results: The study of the genome sequence of CСHFV from GenBank demonstrated that isolates from the Turkestan region belonged to genetic groups Asia-1 and Asia-2. Conclusions: For the first time in Kazakhstan’s history, a phylogenetic analysis of RNA sequences of viruses from patients with CCHF was performed in the Turkestan region, as a result of which genetic groups Asia-1, reassortant Asia-1, and Asia-2 were established